Overview

A Study of DPC 817 in HIV-Infected Males

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmasset
Treatments:
Dexelvucitabine